Ahead of IWD24, BioMarin MD and author of Advance Australia Fairly, Dr Kathryn Evans, questions pharma’s pace of change in gender equality.
Ozempic or Wegovy? Mounjaro or Zepound? With some therapies now getting two names, what do they actually mean?
We look at two of the biggest HTA options on the table to see where they came from, and what they are likely to mean for Australia.
First opioids and now spinal cord stimulators. Should companies walk away from pain rather than risk more reputational damage?
OP-ED: Are a few fast-access carrots enough to get Australia up the launch sequence for new medicines, or will it require a pot of gold?
OP-ED: ‘For the first time in more than 30 years, we have a substantial set of options for bold reform,’ says Medicines Australia Chair, Dr Anna Lavelle.
In our last edition for 2023, we looked at the issues and events that shaped the year. MedNews returns on 15 January 2024.
Medicines Australia wants to have a long conversation with Australians about the PBS, but how honest will this conversation be?